SPECIAL FEATURE – Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product

Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.

CLINICAL TRIALS SOLUTIONS – Cracking Down on the Rising Costs of Drug Development: How Pinpointing the Complexity of Individual Patients Can Improve Success Rates

Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.

FREEZE-DRYING MICROSCOPY – Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques

Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.

EXCLUSIVE WEBINARS

11/5/2021

WEBINAR – ILC Dover: Handling Potent Products in a Sterile Environment

The need for flexible solutions for potent product handling is increasing. We’ll discuss the proven benefits of aseptic isolator systems in sterile environments and take a look at real feedback from real customers of ours in an upcoming webinar on Tuesday, November 16th at 11:00 AM EST.

EXCLUSIVE WHITEPAPERS

EXCLUSIVE ONLINE CONTENT

6/23/2022

Silo Pharma Expands License Agreement & Patent Portfolio

Silo Pharma, Inc. recently announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting….

6/22/2022

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

Pasithea Therapeutics Corp. recently announced its acquisition of Alpha-5 integrin, LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (ALS) and….